Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26194052 | 1.00 | FUCA1 (0.35) | FUCA1 | |
| SCHEMBL19129670 | 1.00 | FUCA1 (0.35) | FUCA1 | |
| SCHEMBL17340987 | 0.98 | FUCA1 (0.38) | FUCA1 | |
| SCHEMBL14159315 | 0.83 | FUCA1 (0.37) | FUCA1 | |
| SCHEMBL22843464 | 0.81 | — | — | |
| SCHEMBL7996542 | 0.80 | FUCA1 (0.38) | FUCA1 | |
| SCHEMBL11587459 | 0.80 | — | — | |
| SCHEMBL26138058 | 0.79 | MAPK1 (0.33) | — | |
| SCHEMBL14318798 | 0.78 | FUCA1 (0.37) | FUCA1 | |
| SCHEMBL25582003 | 0.78 | FUCA1 (0.35) | FUCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9597344-B2 | Sonosensitive liposome, pharmaceutical composition including the same, and method of delivering active agent to subject using the sonosensitive liposome | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2017-03-21 | — | — | US | disclosed |
| US-9220718-B2 | Sonosensitive liposome, pharmaceutical composition including the same, and method of delivering active agent to subject using the sonosensitive liposome | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2015-12-29 | — | — | US | disclosed |
| US-20150352039-A1 | SONOSENSITIVE LIPOSOME, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME, AND METHOD OF DELIVERING ACTIVE AGENT TO SUBJECT USING THE SONOSENSITIVE LIPOSOME | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2015-12-10 | — | — | US | disclosed |
| US-20150150971-A1 | SONOSENSITIVE LIPOSOME, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME, AND METHOD OF DELIVERING ACTIVE AGENT TO SUBJECT USING THE SONOSENSITIVE LIPOSOME | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150150971-A1 | SONOSENSITIVE LIPOSOME, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME, AND METHOD OF DELIVERING ACTIVE AGENT TO SUBJECT USING THE SONOSENSITIVE LIPOSOME | SON, LIPA, LIPE | FUCA1 2873/4885 |
| US-20150352039-A1 | SONOSENSITIVE LIPOSOME, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME, AND METHOD OF DELIVERING ACTIVE AGENT TO SUBJECT USING THE SONOSENSITIVE LIPOSOME | SON, LIPA, LIPE | FUCA1 2873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.